04/18/2003 Page 1 10019976



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1626gms

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

				·
* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * *
MENT	1			Web Page URLs for STN Seminar Schedule - N. America
NEWS	1	Apr	Λ0	wack case for self-help around the clock
NEWS		Jun		New e-mail delivery for search results now available
NEWS				PHARMAMarketLetter(PHARMAML) - new on STN
NEWS		Aug		Aquatic Toxicity Information Retrieval (AQUIRE)
NEWS	5	Aug	19	now available on STN
	_	7	20	Sequence searching in REGISTRY enhanced
NEWS	6			JAPIO has been reloaded and enhanced
NEWS				Experimental properties added to the REGISTRY file
NEWS		Sep Sep	16	CA Section Thesaurus available in CAPLUS and CA
NEWS				CASREACT Enriched with Reactions from 1907 to 1985
NEWS				prijerrin adds new search fields
NEWS				Nutraceuticals International (NUTRACEUT) now available on STN
NEWS		Nov		DKILIT has been renamed APOLLIT
NEWS		Nov		More calculated properties added to REGISTRY
NEWS		Dec		GCA files on STN
NEWS NEWS		Dec		PCTFILL now covers WP/PCT Applications from 1978 to date
NEWS NEWS				TOYCENTER enhanced with additional content
NEWS		Dec		Adia Clinical Trials Insight now available on SIN
NEWS NEWS		Jan		Simultaneous left and right truncation added to COMPENDEX,
MEMS	19	ban	2,7	ENERGY, INSPEC
NEWS	20	Feb	13	CANCERLIT is no longer being updated
NEWS			24	METADEX enhancements
NEWS	22	Feb		PCTGEN now available on STN
NEWS	23	Feb	24	TEMA now available on STN
NEWS			26	NTIS now allows simultaneous left and right truncation
NEWS		Feb	26	poweru now contains images
NEWS	26	Mar	04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar	19	APOLLIT offering free connect time in April 2003
NEWS			20	EVENTLINE will be removed from STN
NEWS			24	PATDPAFULL now available on STN
NEWS	3 0	Mar	24	Additional information for trade-named substances without
				structures available in REGISTRY
NEWS	3 3 1	Mar	24	Indexing from 1957 to 1966 added to records in CA/CAPLUS
NEWS	3 3 2		: 11	Display formats in DGENE enhanced
NEWS	3 3 3	Apı	14	MEDLINE Reload
NEWS	3 3 4	Apı	17	Polymer searching in REGISTRY enhanced
				TO ME OLD CHERT
NEW:	S EX	PRES	3 A	pril 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
			M	ACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
			A	ND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
	s HO		S	TN Operating Hours Plus Help Desk Availability
	S IN		G	eneral Internet Information
NEW	s Lo	GIN	W	elcome Banner and News Items

10019976 Page 2 04/18/2003

NEWS PHONE Direct Dial and Telecommunication Network Access to STN NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:26:57 ON 18 APR 2003

=> FIL REGISTRY
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 14:27:05 ON 18 APR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 APR 2003 HIGHEST RN 503414-07-1 DICTIONARY FILE UPDATES: 17 APR 2003 HIGHEST RN 503414-07-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10019976.str

L1 STRUCTURE UPLOADED

=> d l1 L1 HAS NO ANSWERS L1 STR Page 3

ANSWERS



Structure attributes must be viewed using STN Express query preparation.

=> s 11 SAMPLE SEARCH INITIATED 14:27:29 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 698 TO ITERATE

698 ITERATIONS 100.0% PROCESSED INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\* BATCH \*\*COMPLETE\*\* 12376 TO 15544 PROJECTED ITERATIONS: 752 TO 1688

PROJECTED ANSWERS:

50 SEA SSS SAM L1 L2

=> s l1 sss full FULL SEARCH INITIATED 14:27:36 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 13698 TO ITERATE


100.0% PROCESSED 13698 ITERATIONS SEARCH TIME: 00.00.02

1174 SEA SSS FUL L1 L3

=> Uploading 10019976a.str

STRUCTURE UPLOADED L4

=> d 14L4 HAS NO ANSWERS STR L4



Structure attributes must be viewed using STN Express query preparation.

=> s 14

SAMPLE SEARCH INITIATED 14:29:49 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -15 TO ITERATE

100.0% PROCESSED SEARCH TIME: 00.00.01

15 ITERATIONS

4 ANSWERS

FULL FILE PROJECTIONS:

ONLINE \*\*COMPLETE\*\*

BATCH

\*\*COMPLETE\*\*

PROJECTED ITERATIONS:

68 TO 532

PROJECTED ANSWERS:

4 TO

**L**5

4 SEA SSS SAM L4

=> s 14 sss full

FULL SEARCH INITIATED 14:29:57 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -330 TO ITERATE

100.0% PROCESSED

330 ITERATIONS

SEARCH TIME: 00.00.01

56 SEA SSS FUL L4

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

FULL ESTIMATED COST

ENTRY

TOTAL SESSION

56 ANSWER

297.50 297.71

FILE 'CAPLUS' ENTERED AT 14:30:15 ON 18 APR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Apr 2003 VOL 138 ISS 17 FILE LAST UPDATED: 17 Apr 2003 (20030417/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

 $=> s 16^{\circ}$ L7

=> d ibib abs hitstr 17 tot

ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 2002:312317 CAPLUS

DOCUMENT NUMBER:

137:56986

2-(Anilinomethyl)imidazolines as .alpha.1 Adrenergic TITLE:

Receptor Agonists: the Discovery of .alpha.la Subtype

Selective 2'-Alkylsulfonyl-Substituted Analogues

AUTHOR (S): Hodson, Stephen J.; Bishop, Michael J.; Speake, Jason

D.; Navas, Frank, III; Garrison, Deanna T.; Bigham, Eric C.; Saussy, David L., Jr.; Liacos, James A.; Irving, Paul E.; Gobel, M. Jeffrey; Sherman, Bryan W.

GlaxoSmithKline Research Laboratories, Research CORPORATE SOURCE:

Triangle Park, NC, 27709-3398, USA

(2002), 45(11 Journal of Medicinal Chemistry SOURCE:

2229-2239

CODEN: JMCMAR; ISSN: 0022-2623

American Chemical Society PUBLISHER:

Journal DOCUMENT TYPE: LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:56986

A series of 2'-alkylthio-2-(anilinomethyl)imidazolines were prepd. to examine the effect of the alkyl group size, sulfur oxidn. state, and Ph ring substitution on ligand binding and agonism of .alpha.-adrenergic receptor subtypes .alpha.1a, .alpha.1b, .alpha.1d, .alpha.2a, and

.alpha.2c. Binding at all receptor subtypes decreased for compds. in the sulfone oxidn. state as compared to their sulfide analogs. While sulfides were generally potent, nonselective agonists, sulfones exhibited .alpha.la subtype selectivity in a cell-based functional assay. One of the sulfones

was 250-7000-fold selective for .alpha.1a vs. all other subtypes.

TΤ 67083-77-6P 439291-53-9P 439291-54-0P

439291-56-2P 439291-59-5P 439291-62-0P

439291-64-2P 439291-66-4P 439291-70-0P

439291-72-2P 439291-74-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and structure activity relationships of 2-

(anilinomethyl)imidazolines as .alpha.1 adrenergic receptor agonists)

RN67083-77-6 CAPLUS

CN

1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylthio)phenyl]-,

monohydrochloride (9CI) (CA INDEX NAME)

● HCl

439291-53-9 CAPLUS RN

1H-Imidazole-2-methanamine, N-[2-(ethylthio)phenyl]-4,5-dihydro-, CN (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM1

CRN 439291-52-8

C12 H17 N3 S CMF

10019976

2 CM

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

439291-54-0 CAPLUS RN

1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-[(1-methylethyl)thio]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

439291-56-2 CAPLUS RN1H-Imidazole-2-methanamine, N-[3-fluoro-2-(methylthio)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME) CN

1 CM

CRN 439291-55-1 CMF C11 H14 F N3 S

CM

110-17-8 CRN CMF C4 H4 O4

Double bond geometry as shown.

RN 439291-59-5 CAPLUS CN 1H-Imidazole-2-methanamine, N-[4-fluoro-2-(methylthio)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439291-58-4 CMF C11 H14 F N3 S

$$\begin{array}{c} \overset{H}{\underset{N}{\bigvee}} \text{CH}_2 - \text{NH} \\ & \overset{F}{\underset{\text{SMe}}{\bigvee}} \end{array}$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 439291-62-0 CAPLUS CN 1H-Imidazole-2-methanamine, N-[5-fluoro-2-(methylthio)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439291-61-9 CMF C11 H14 F N3 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 439291-64-2 CAPLUS CN 1H-Imidazole-2-methanamine, N-[2-fluoro-6-(methylthio)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439291-63-1 CMF C11 H14 F N3 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 439291-66-4 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylthio)-5(trifluoromethyl)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439291-65-3 CMF C12 H14 F3 N3 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN439291-70-0 CAPLUS CN

1H-Imidazole-2-methanamine, 4,5-dihydro-N-[5-methyl-2-(methylthio)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM

CRN 439291-69-7 CMF C12 H17 N3 S

$$\begin{array}{c} \text{Me} \\ \text{N} \\ \text{N} \\ \text{CH}_2 - \text{NH} \\ \end{array}$$
 SMe

CM

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN439291-72-2 CAPLUS CN

1H-Imidazole-2-methanamine, 4,5-dihydro-N-[5-methoxy-2-(methylthio)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439291-71-1 CMF C12 H17 N3 O S

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 439291-74-4 CAPLUS CN 1H-Imidazole-2-methanamine, N-[5-chloro-2-(methylthio)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439291-73-3 CMF C11 H14 C1 N3 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

IT 305809-48-7P 305809-50-1P 305809-52-3P 305809-54-5P 305809-55-6P 305809-57-8P 305809-59-0P 305809-61-4P 305809-63-6P 305809-64-7P 305811-04-5P 439291-51-7P 439291-68-6P 439291-76-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and structure activity relationships of 2-(anilinomethyl)imidazolines as .alpha.1 adrenergic receptor agonists) RN 305809-48-7 CAPLUS 1H-Imidazole-2-methanamine, N-[2-(ethylsulfonyl)phenyl]-4,5-dihydro-, CN (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME) CMCRN 305809-47-6 CMF C12 H17 N3 O2 S

CM2

CRN 110-17-8 CMF C4 H4 O4


Double bond geometry as shown.

RN305809-50-1 CAPLUS 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-[(1-methanamine)])CN methylethyl)sulfonyl]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX

had dutt

CM 1

CRN 305809-49-8 CMF C13 H19 N3 O2 S



CM

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-52-3 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[2-fluoro-6-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-51-2 CMF C11 H14 F N3 O2 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-54-5 CAPLUS

1H-Imidazole-2-methanamine, N-[4-fluoro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CN

CRN 305809-53-4 CMF C11 H14 F N3 O2 S

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-55-6 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(propylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

## ● HCl

RN 305809-57-8 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[3-fluoro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-56-7 CMF C11 H14 F N3 O2 S

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-59-0 CAPLUS CN 1H-Imidazole-2-metha

1H-Imidazole-2-methanamine, N-[5-fluoro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-58-9

CMF C11 H14 F N3 O2 S

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-61-4 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[5-methoxy-2-(methylsulfonyl)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-60-3 CMF C12 H17 N3 O3 S

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-63-6 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[5-methyl-2-(methylsulfonyl)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-62-5 CMF C12 H17 N3 O2 S

$$\begin{array}{c|c} & \text{Me} \\ & \text{N} \\ & \text{N} \\ & \text{O} \\ & \text{S} \\ & \text{N} \\ & \text{O} \end{array}$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-64-7 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c}
H \\
N \\
CH_2-NH \\
O \\
Me
\end{array}$$

● HCl

RN 305811-04-5 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[5-chloro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305811-03-4

CMF C11 H14 C1 N3 O2 S

$$C1$$

$$N$$

$$CH_2-NH$$

$$O=S-Me$$

$$0$$

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

RN 439291-51-7 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylsulfinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me-S} \\ \text{H} \\ \text{N} \\ \text{CH}_2 - \text{NH} \end{array}$$

● HCl

RN 439291-68-6 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylsulfonyl)-5-(trifluoromethyl)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439291-67-5 CMF C12 H14 F3 N3 O2 S

$$CF_3$$
 $CH_2-NH$ 
 $O=S-Me$ 

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 439291-76-6 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[4-chloro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439291-75-5 CMF C11 H14 C1 N3 O2 S

$$\begin{array}{c} H \\ N \\ N \\ O = S - Me \\ O \\ \end{array}$$

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

CO2H

REFERENCE COUNT:

36

THERE RE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 2000:790481 CAPLUS 133:350215

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

agonists

Apylaminomethylimidazolines as .alpha.1A adrenoceptor Bigham, Eric Cleveland; Bishop, Michael Joseph;

Drewry, Barid Harold; Garrison, Deanna Trojan; Hodson, Step on Joseph; Navas, Frank, III; Speake, Jason D.

PATENT ASSIGNEE(S): Claxo Group Limited, UK; Navas Iii, Frank SOURCE: PCT Int. Appl., 75 pp.

DOCUMENT TYPE: LANGUAGE:

Patent English

CODEN: PIXXD2

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT	NO.	KIND	DATE	APPLICATION NO	DATE
WO 2000 W:	AE, AG, CU, CZ, ID, IL, LV, MA, SG, SI,	AL, AM, DE, DK, IN, IS, MD, MG, SK, SL,	AT, AU, AZ, DM, DZ, EE, JP, KE, KG, MK, MN, MW,	ES, FI, GB, GD, KP, KR, KZ, LC, MX, NO, NZ, PL, TT, TZ, UA, UG.	20000428 BY, CA, CH, CN, CR, GE, GH, GM, HR, HU, LK, LR, LS, LT, LU, PT, RO, RU, SD, SE, US, UZ, VN, YU, ZA,
	GH, GM, DK, ES, CG, CI,	KE, LS, FI, FR, CM, GA,	MW, SD, SL, GB, GR, IE, GN, GW, ML.	SZ, TZ, UG, ZW, IT, LU, MC, NL, MR, NE, SN, TD	AT, BE, CH, CY, DE, PT, SE, BF, BJ, CF, TG
EP 1175	406	A1	20020130	EP 2000-925251	20000428
R:	IE, SI,	CH, DE, LT, LV,	DK, ES, FR, FI, RO	GB, GR, IT, LI,	LU, NL, SE, MC, PT,
JP 2002 PRIORITY APP	543187 LN. INFO	T2 .:	(	JP 2000-615394 GB 1999-10110 JO 2000-EP3848	A 19990430

OTHER SOURCE(S):

MARPAT 133:350215

AB Title compds. I [R2-R5 = H, halogen, -OH, alkyl, alkoxy, alkylthio, CF3, gtoreq. 2 of R2-R5 = H; R6 = H, Me; R1 = S(0)nR7 (n = 1, 2), SO2NHR8, COR9, NR10R11, CR12:NOR13, (un)substituted Ph, heterocyclic; R7, R8 = alkyl, fluoroalkyl; R9 = alkyl, fluoroalkyl, (un)substituted NH2, NHNH2; (un)substituted alkyl; R11 = cycloalkyl, cyclopropylmethyl, alkenyl, (un)substituted alkyl; R12 = H, alkyl; R13 = alkyl] were prepd. for use in incontinence. Thus, 2-MeSC6H4NH2 was treated with 2-chloromethyl-2-fumarate, which was active as an agonist for cloned human .alpha.1A

IT 305809-66-9P 305809-68-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylaminomethylimidazolines as .alpha.1A adrenoceptor agonists)

RN 305809-66-9 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylsulfinyl)phenyl]-, (-)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM ]

CRN 305809-65-8 CMF C11 H15 N3 O S

Rotation (-).

CM 2

CRN 110-17-8 CMF C4 H4 O4 Double bond geometry as shown.

RN 305809-68-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylsulfinyl)phenyl]-,
(+)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-67-0 CMF C11 H15 N3 O S

Rotation (+).

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

IT305809-46-5P 305809-48-7P 305809-50-1P 305809-52-3P 305809-54-5P 305809-55-6P 305809-57-8P 305809-59-0P 305809-61-4P 305809-63-6P 305809-64-7P 305810-08-6P 305810-10-0P 305811-04-5P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of arylaminomethylimidazolines as .alpha.1A adrenoceptor agonists) RN305809-46-5 CAPLUS 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylsulfonyl)phenyl]-, CN(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME) CM 1 CRN 305809-45-4 CMF C11 H15 N3 O2 S

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-48-7 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[2-(ethylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-47-6 CMF C12 H17 N3 O2 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-50-1 CAPLUS

1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-[(1-methylethyl)sulfonyl]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CN

CRN 305809-49-8 CMF C13 H19 N3 O2 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-52-3 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[2-fluoro-6-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-51-2 CMF C11 H14 F N3 O2 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-54-5 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[4-fluoro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-53-4 CMF C11 H14 F N3 O2 S

$$\begin{array}{c|c} H & & \\ N & & \\ N & & \\ O & & \\ S - Me \\ 0 & & \\ \end{array}$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-55-6 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(propylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 305809-57-8 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[3-fluoro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-56-7 CMF C11 H14 F N3 O2 S

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-59-0 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[5-fluoro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-58-9 CMF C11 H14 F N3 O2 S

$$CH_2-NH$$

$$O=S-Me$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-61-4 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[5-methoxy-2-

(methylsulfonyl)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM1

CRN 305809-60-3 CMF C12 H17 N3 O3 S

$$\begin{array}{c|c} & \text{OMe} \\ \hline \\ N \\ \hline \\ N \\ \hline \\ O \\ \hline \\ O \\ \hline \\ S \\ O \\ \hline \\ O \\ \end{array}$$

CM2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN305809-63-6 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[5-methyl-2-(methylsulfonyl)phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM

CRN 305809-62-5 CMF C12 H17 N3 O2 S

$$\begin{array}{c|c}
H \\
N \\
CH_2-NH
\end{array}$$

$$\begin{array}{c|c}
S-Me \\
0
\end{array}$$

CM2

CRN 110-17-8 CMF C4 H4 O4 Double bond geometry as shown.

RN 305809-64-7 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c} \stackrel{H}{\stackrel{N}{\stackrel{N}{\longrightarrow}}} CH_2 - NH \\ \stackrel{N}{\stackrel{N}{\stackrel{N}{\longrightarrow}}} O \\ \stackrel{Me}{\stackrel{N}{\stackrel{N}{\longrightarrow}}} O \end{array}$$

## ● HCl

RN 305810-08-6 CAPLUS

CN Benzenesulfonamide, 2-[[(4,5-dihydro-1H-imidazol-2-yl)methyl]amino]-N-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305810-07-5 CMF C11 H16 N4 O2 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305810-10-0 CAPLUS

CN Benzenesulfonamide, 2-[[(4,5-dihydro-1H-imidazol-2-yl)methyl]amino]-N-ethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CRN 305810-09-7 CMF C12 H18 N4 O2 S

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305811-04-5 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[5-chloro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305811-03-4 CMF C11 H14 C1 N3 O2 S

$$C1$$

$$N$$

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

IT 305811-05-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of arylaminomethylimidazolines as .alpha.1A adrenoceptor agonists)

RN 305811-05-6 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

IT 305809-45-4P 305809-47-6P 305809-58-9P

305809-60-3P 305809-62-5P 305810-07-5P

305810-09-7P 305811-03-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylaminomethylimidazolines as .alpha.1A adrenoceptor agonists)

RN 305809-45-4 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylsulfonyl)phenyl]-(9CI) (CA INDEX NAME)

RN 305809-47-6 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[2-(ethylsulfonyl)phenyl]-4,5-dihydro- (9CI) (CA INDEX NAME)

RN 305809-58-9 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[5-fluoro-2-(methylsulfonyl)phenyl]-4,5-dihydro-(9CI) (CA INDEX NAME)

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

RN 305809-60-3 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[5-methoxy-2-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

RN 305809-62-5 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[5-methyl-2-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} \\ & \text{N} \\ & \text{N} \\ & \text{O} \\ & \text{S} \\ & \text{O} \end{array}$$

RN 305810-07-5 CAPLUS

CN Benzenesulfonamide, 2-[[(4,5-dihydro-1H-imidazol-2-yl)methyl]amino]-N-methyl- (9CI) (CA INDEX NAME)

RN 305810-09-7 CAPLUS

CN Benzenesulfonamide, 2-[[(4,5-dihydro-1H-imidazol-2-yl)methyl]amino]-N-ethyl- (9CI) (CA INDEX NAME)

RN 305811-03-4 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[5-chloro-2-(methylsulfonyl)phenyl]-4,5-dihydro-(9CI) (CA INDEX NAME)

$$C1$$

$$N$$

$$CH_2-NH$$

$$O=S-Me$$

$$0$$

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 1982:81362 CAPLUS

DOCUMENT NUMBER: 96:81362

TITLE: Imidazoline derivatives and their pesticidal use

INVENTOR(S): Kristinsson, Haukur; Traber, Walter

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Can., 29 pp. Division of Can. Appl. No. 290,708.

CODEN: CAXXA4

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

10019976	Page 3	T	04/18/2003	04/18/2003		
CA 1109787	A2	19810929	CA 1980-356272	19800715		
CH 630507	A	19820630	CH 1977-12390	19771011		
BE 860781	A1	19780516	BE 1977-182582	19771114		
CA 1104143	A1	19810630	CA 1977-290708	19771114		
ZA 7706801	Α	19780927	ZA 1977-6801	19771115		
CS 194822	P	19791231	CS 1977-7520	19771115		
PRIORITY APPLN. INFO	.:		CH 1976-14401	19761116		
			CH 1976-14402	19761116		
			CH 1977-12390	19771011		
		•	CA 1977-290708	19771114		

04/19/2002

Dago 21

Ι

GI


$$\begin{array}{c|c}
 & R5 \\
 & R4 \\
 & R1 \\
 & R3
\end{array}$$

AB Hydrochlorides and free bases of anilinomethylimidazolines I (where R1 = H or alkyl; R2 = H, Me, pentyl, Bu, or substituted Ph; R3 = H, halo, Me, MeO, etc; R4 = R5 = H, halo, or Me) are pesticides. Thus, compns. contg. 2-(2'-methyl-3'-chlorophenylaminomethyl)-2-imidazoline (II) [80548-49-8] or an acid addn. salt with an inorg. or org. acid, together with a liq. or solid carrier or additive are suitable for ectoparasite control. Contact application of II HCl [67084-18-8] to engorged Boophilus microplus females resulted in 100% inhibition of oviposition at a min. concn. of 100 ppm in lab. tests. Syntheses of these imidazoline derivs. are described. IT 67083-77-6P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and pesticidal activity of)

RN 67083-77-6 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylthio)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 1978:541911 CAPLUS

DOCUMENT NUMBER: 89:141911

TITLE: Pesticidal composition for combatting ectoparasites

and microorganisms

INVENTOR(S): Kristinsson, Haukur; Traber, Walter

10019976

Page 32

04/18/2003

PATENT ASSIGNEE(S):

Ciba-Geigy A.-G., Switz.

SOURCE:

Ger. Offen., 35 pp. CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATEN	T NO.	KIND	DATE	AF	PLICATION NO.	DATE
	50902	A1	19780524	DE	1977-2750902	19771114
CH 63	0507	A	19820630	CH	1977-12390	19771011
NL 77	12401	A	19780518	NL	1977-12401	19771110
BR 77	07589	Α	19780620	BR	1977-7589	19771111
BE 86	0781	A1	19780516	BE	1977-182582	19771114
GB 15	92699	A	19810708	GB	1977-47367	19771114
IL 53	374	A1	19830615	IL	1977-53374	19771114
ZA 77	06801	A	19780927	ZA	1977-6801	19771115
ES 46	4150	A1	19790101	ES	1977-464150	19771115
AU 77	30654	A1	19790524	AU	1977-30654	19771115
AU 52	6754	B2	19830127			
CS 19	4822	P	19791231	CS	1977-7520	19771115
JP 53	063378	A2	19780606		1977-137762	19771116
FR 23	80733	A1	19780915		1977-34431	19771116
FR 23	80733	B1	19820730			
FR 23	81030	A1	19780915	FR	1978-16218	19780531
FR 23	81030	B1	19821001		10210	10,00001
PRIORITY A	PPLN. INFO.:			CH 19	76-14401	19761116
					76-14402	19761116
					77-12390	19771011
GI				C11 1 J	11 12370	19//1011
<del>-</del>						

The 2-phenylaminomethyl-2-imidazolines I (R1 = H or C1-10 alkyl; R2 = H, AB C1-10 alkyl or substituted Ph; R3, R4, and R5 = H, C1-5 alkyl, C1-5 alkoxy, alkylthio, OH, halo, NO2, CN, or CF3; R3R4 = 1.4-butadienyl) are acaricides and fungicides. Thus, the LC100 of 2-(2,3dimethylphenylaminomethyl)-2-imidazoline-HCl (II) [67084-33-7] for Ablyomma hebraeum was 1 ppm. The synthesis of I is given. II was prepd. by the reaction of 2-chloromethyl-2-imidazoline-HCl [13338-49-3] with 2,3-dimethylaniline [87-59-2].


ΙT 67083-77-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and acaricidal and fungicidal activity of)

Ι

RN 67083-77-6 CAPLUS

1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-(methylthio)phenyl]-, CN monohydrochloride (9CI) (CA INDEX NAME)



=> FIL REGISTRY COST IN U.S. DOLLARS

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 22.31 320.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE

-2.60
-2.60

FILE 'REGISTRY' ENTERED AT 14:36:09 ON 18 APR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 APR 2003 HIGHEST RN 503414-07-1 DICTIONARY FILE UPDATES: 17 APR 2003 HIGHEST RN 503414-07-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

Uploading 10019976b.str

L8 STRUCTURE UPLOADED

=> d 18 L8 HAS NO ANSWERS L8 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 18

SAMPLE SEARCH INITIATED 14:36:36 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -2 TO ITERATE

100.0% PROCESSED

2 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS:

2 TO 124

PROJECTED ANSWERS:

2 TO 124

1.9

2 SEA SSS SAM L8

=> FIL CAPLUS

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.40 320.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL ENTRY SESSION

CA SUBSCRIBER PRICE 0.00 -2.60 FILE 'CAPLUS' ENTERED AT 14:36:41 ON 18 APR 2003

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Apr 2003 VOL 138 ISS 17 FILE LAST UPDATED: 17 Apr 2003 (20030417/ED)

10019976 Page 35 04/18/2003

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 14:26:57 ON 18 APR 2003)

FILE 'REGISTRY' ENTERED AT 14:27:05 ON 18 APR 2003

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 1174 S L1 SSS FULL

L4 STRUCTURE UPLOADED

L5 4 S L4

L6 56 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:30:15 ON 18 APR 2003

L7 4 S L6

FILE 'REGISTRY' ENTERED AT 14:36:09 ON 18 APR 2003

L8 STRUCTURE UPLOADED

L9 2 S L8

FILE 'CAPLUS' ENTERED AT 14:36:41 ON 18 APR 2003

=> s 18

## REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 14:36:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 2 TO 124
PROJECTED ANSWERS: 2 TO 124

L10 2 SEA SSS SAM L8

L11 2 L10

=> d ibib abs hitstr l11 tot

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:

2002:312317 CAPLUS

DOCUMENT NUMBER:

137:56986

TITLE:

2-(Anilinomethyl)imidazolines as .alpha.1 Adrenergic Receptor Agonists: the Discovery of .alpha.1a Subtype Selective 2'-Alkylsulfonyl-Substituted Analogues

10019976

Page 36

04/18/2003

AUTHOR (S):

Hodson, Stephen J.; Bishop, Michael J.; Speake, Jason D.; Navas, Frank, III; Garrison, Deanna T.; Bigham, Eric C.; Saussy, David L., Jr.; Liacos, James A.; Irving, Paul E.; Gobel, M. Jeffrey; Sherman, Bryan W.

CORPORATE SOURCE:

GlaxoSmithKline Research Laboratories, Research

Triangle Park, NC, 27709-3398, USA

SOURCE: '

Journal of Medicinal Chemistry (2002), 45(11),

2229-2239

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER:

American Chemical Society

DOCUMENT TYPE: LANGUAGE: Journal English

OTHER SOURCE(S):

CASREACT 137:56986

As series of 2'-alkylthio-2-(anilinomethyl)imidazolines were prepd. to examine the effect of the alkyl group size, sulfur oxidn. state, and Ph ring substitution on ligand binding and agonism of .alpha.-adrenergic receptor subtypes .alpha.la, .alpha.lb, .alpha.ld, .alpha.2a, and .alpha.2c. Binding at all receptor subtypes decreased for compds. in the sulfone oxidn. state as compared to their sulfide analogs. While sulfides were generally potent, nonselective agonists, sulfones exhibited .alpha.la subtype selectivity in a cell-based functional assay. One of the sulfones was 250-7000-fold selective for .alpha.la vs. all other subtypes.

IT 305809-50-1P 305809-59-0P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and structure activity relationships of 2-

(anilinomethyl)imidazolines as .alpha.1 adrenergic receptor agonists)


RN 305809-50-1 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-[(1-

methylethyl)sulfonyl]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-49-8 CMF C13 H19 N3 O2 S



CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

HO<sub>2</sub>C E CO<sub>2</sub>H

RN 305809-59-0 CAPLUS

1H-Imidazole-2-methanamine, N-[5-fluoro-2-(methylsulfonyl)phenyl]-4,5dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM

CRN 305809-58-9 CMF C11 H14 F N3 O2 S

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

CM

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

CO2H

REFERENCE COUNT:

THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 2000:790481 CAPLUS

36

DOCUMENT NUMBER:

TITLE:

133-350215

INVENTOR(S):

Arylaminomethylimidazolines as .alpha.1A adrenoceptor agorists

Bigham, Erid Cleveland; Bishop, Michael Joseph;
Drewry, David Harold; Garrison, Deanna Trojan; Hodson,

Stephen Joseph; Navas, Frank, III; Speake, Jason D. Glaxo Group Limited, UK; Navas Iii, Frank

PCT Int. Appl., 75 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT ASSIGNEE(S):

PATENT NO. KIND DATE APPLICATION NO. DATE - **- -** ------WO 2000-EP3848 20000428 WO 2000066563 A1 20001109 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,

ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1175406 A1 20020130 EP 2000-925251 20000428 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO JP 2002543187 T2 20021217 JP 2000-615394 20000428 PRIORITY APPLN. INFO.: GB 1999-10110 A 19990430 WO 2000-EP3848 W 20000428 OTHER SOURCE(S): MARPAT 133:350215 GI

$$R^{3}$$
 $R^{4}$ 
 $R^{5}$ 
 $R^{1}$ 
 $R^{6}$ 
 $R^{6}$ 
 $R^{1}$ 
 $R^{6}$ 
 $R^{1}$ 
 $R^{6}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{1}$ 
 $R^{6}$ 

Title compds. I [R2-R5 = H, halogen, -OH, alkyl, alkoxy, alkylthio, CF3, .gtoreq. 2 of R2-R5 = H; R6 = H, Me; R1 = S(O)nR7 (n = 1, 2), SO2NHR8, COR9, NR10R11, CR12:NOR13, (un)substituted Ph, heterocyclic; R7, R8 = alkyl, fluoroalkyl; R9 = alkyl, fluoroalkyl, (un)substituted NH2, NHNH2; R10 = H, alkyl; R11 = cycloalkyl, cyclopropylmethyl, alkenyl, (un)substituted alkyl; R12 = H, alkyl; R13 = alkyl] were prepd. for use in the treatment of .alpha.1A-mediated diseases or conditions such as urinary incontinence. Thus, 2-MeSC6H4NH2 was treated with 2-chloromethyl-2-imidazoline-HCl and oxidized to give I [R1 = SO2Me, R2-R6 = H] as the fumarate, which was active as an agonist for cloned human .alpha.1A receptors.

IT 305809-50-1P 305809-59-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of arylaminomethylimidazolines as .alpha.lA adrenoceptor agonists)

RN 305809-50-1 CAPLUS

CN 1H-Imidazole-2-methanamine, 4,5-dihydro-N-[2-[(1-methylethyl)sulfonyl]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-49-8 CMF C13 H19 N3 O2 S

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

RN 305809-59-0 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[5-fluoro-2-(methylsulfonyl)phenyl]-4,5-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 305809-58-9 CMF C11 H14 F N3 O2 S

$$CH_2-NH$$

$$O=S-Me$$

$$O$$

CM 2

CRN 110-17-8 CMF C4 H4 O4

Double bond geometry as shown.

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10019976	Page 40	04/18/2003
		01/10/2003

=> log y COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL
FULL ESTIMATED COST	9.91	SESSION 331.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY -1.30	SESSION -3.90

STN INTERNATIONAL LOGOFF AT 14:38:00 ON 18 APR 2003